Amgen Stock Price, News & Analysis (NASDAQ:AMGN)

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

20 equities research analysts have issued 12 month target prices for Amgen's shares. Their AMGN share price targets range from $200.00 to $320.00. On average, they predict the company's share price to reach $278.15 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

Amgen's stock was trading at $262.64 at the beginning of 2023. Since then, AMGN shares have increased by 1.9% and is now trading at $267.57.
View the best growth stocks for 2023 here.

Amgen saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 6,770,000 shares, an increase of 5.5% from the October 31st total of 6,420,000 shares. Based on an average trading volume of 2,420,000 shares, the days-to-cover ratio is currently 2.8 days. Approximately 1.3% of the company's shares are sold short.
View Amgen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 30th 2024.
View our AMGN earnings forecast.

Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, October, 31st. The medical research company reported $4.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.65 by $0.31. The medical research company earned $6.90 billion during the quarter, compared to analyst estimates of $6.92 billion. Amgen had a trailing twelve-month return on equity of 165.37% and a net margin of 28.20%. The business's revenue was up 3.7% compared to the same quarter last year. During the same period last year, the business posted $4.70 earnings per share.
Read the conference call transcript.

Amgen announced a quarterly dividend on Tuesday, October 24th. Shareholders of record on Friday, November 17th will be given a dividend of $2.13 per share on Friday, December 8th. This represents a $8.52 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Thursday, November 16th.
Read our dividend analysis for AMGN.

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.22%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 60.55%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 43.34% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include Timothy Plan Market Neutral ETF (TPMN), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Pharmaceuticals ETF (PJP), FT Cboe Vest DJIA Dogs 10 Target Income ETF (DOGG) and Invesco Dow Jones Industrial Average Dividend ETF (DJD).

Amgen updated its FY23 earnings guidance on Tuesday, October, 31st. The company provided EPS guidance of $18.20-$18.80 for the period, compared to the consensus earnings per share estimate of $18.36. The company issued revenue guidance of $28.0-$28.4 billion, compared to the consensus revenue estimate of $27.57 billion.

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (2.75%), Morgan Stanley (2.48%), Charles Schwab Investment Management Inc. (2.04%), Northern Trust Corp (1.30%), Bank of New York Mellon Corp (1.02%) and Royal Bank of Canada (0.95%). Insiders that own company stock include Amgen Inc, Jonathan P Graham, Jonathan P Graham, Murdo Gordon, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.